Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Orthopediatrics (KIDS) Research & Development (2016 - 2025)

Orthopediatrics has reported Research & Development over the past 10 years, most recently at $2.3 million for Q4 2025.

  • Quarterly results put Research & Development at $2.3 million for Q4 2025, down 22.53% from a year ago — trailing twelve months through Dec 2025 was $9.1 million (down 17.51% YoY), and the annual figure for FY2025 was $9.1 million, down 17.51%.
  • Research & Development for Q4 2025 was $2.3 million at Orthopediatrics, down from $2.3 million in the prior quarter.
  • Over the last five years, Research & Development for KIDS hit a ceiling of $3.0 million in Q1 2024 and a floor of $1.3 million in Q3 2021.
  • Median Research & Development over the past 5 years was $2.3 million (2025), compared with a mean of $2.3 million.
  • Biggest five-year swings in Research & Development: surged 69.78% in 2023 and later fell 22.53% in 2025.
  • Orthopediatrics' Research & Development stood at $1.6 million in 2021, then surged by 53.73% to $2.5 million in 2022, then rose by 18.2% to $2.9 million in 2023, then dropped by 0.21% to $2.9 million in 2024, then fell by 22.53% to $2.3 million in 2025.
  • The last three reported values for Research & Development were $2.3 million (Q4 2025), $2.3 million (Q3 2025), and $2.2 million (Q2 2025) per Business Quant data.